MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.480
-0.030
-1.99%
Opening 12:34 05/24 EDT
OPEN
1.530
PREV CLOSE
1.510
HIGH
1.530
LOW
1.425
VOLUME
122.48K
TURNOVER
114.52K
52 WEEK HIGH
6.86
52 WEEK LOW
1.260
MARKET CAP
239.56M
P/E (TTM)
-1.3553
1D
5D
1M
3M
1Y
5Y
Adaptimmune Therapeutics: Q1 Earnings Insights
  Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q1 earnings results on Monday, May 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/09 11:57
BRIEF-Adaptimmune Reports First Quarter Financial Results
reuters.com · 05/09 11:42
Adaptimmune Therapeutics Q1 EPS $(0.05) Down From $(0.04) YoY, Sales $3.60M Beat $3.29M Estimate
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.05) per share. This is a 25 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales
Benzinga · 05/09 11:33
Adaptimmune GAAP EPS of -$0.05 beats by $0.19, revenue of $3.6M misses by $1.4M
Adaptimmune press release (NASDAQ:ADAP): Q1 GAAP EPS of -$0.05 beats by $0.19. Revenue of $3.6M (+737.2% Y/Y) misses by $1.4M.
Seekingalpha · 05/09 11:32
Adaptimmune Reports First Quarter Financial Results and Business Update
- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO - - Preclinical data for two novel next-generation T-cell therapies to be presented in two posters at ASGCT...
GlobeNewswire · 05/09 11:30
Earnings Scheduled For May 9, 2022
  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Benzinga · 05/09 08:52
-- Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Posts Q1 Revenue $3.6M, vs. Street Est of $5M
MT Newswires · 05/09 07:35
A Preview Of Adaptimmune Therapeutics's Earnings
Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Adaptimmune Therapeutics will report an earnings per share ...
Benzinga · 05/06 16:11
More
No Data
Learn about the latest financial forecast of ADAP. Analyze the recent business situations of Adaptimmune Therapeutics Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
37.50%Buy
50.00%Hold
12.50%Under-perform
0.00%Sell
Analyst Price Target
The average ADAP stock price target is 5.67 with a high estimate of 9.00 and a low estimate of 2.000.
High9.00
Average5.67
Low2.000
Current 1.480
EPS
Actual
Estimate
-0.20-0.11-0.020.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 118
Institutional Holdings: 110.85M
% Owned: 68.49%
Shares Outstanding: 161.87M
TypeInstitutionsShares
Increased
26
6.70M
New
13
520.38K
Decreased
24
1.72M
Sold Out
14
8.92M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.06%
Pharmaceuticals & Medical Research
-0.48%
Key Executives
Non-Executive Chairman/Independent Director
David Mott
Chief Executive Officer/Director
Adrian Rawcliffe
Chief Financial Officer
Gavin Wood
Chief Operating Officer
William Bertrand
Chief Scientific Officer
Joanna Brewer
Other
John Lunger
Other
Elliot Norry
Other
Cintia Piccina
Other
Helen Tayton-Martin
Non-Executive Director
James Noble
Non-Executive Independent Director
Lawrence Alleva
Non-Executive Independent Director
Ali Behbahani
Non-Executive Independent Director
Barbara Duncan
Non-Executive Independent Director
John Furey
Non-Executive Independent Director
Elliott Sigal
Non-Executive Independent Director
Tal Zvi Zaks
No Data
No Data
About ADAP
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.